Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The investigators major aim is to determine whether there is a difference in the retention of zoledronic acid in multiple myeloma patients, compared to patients with breast cancer metastasis to bone. In addition the investigators wish to analyze if the retention of zoledronic acid is correlated to the extent of bone resorption/formation, and if there is a tendency to changes in retention with sequential treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vejle Hospital
• Collaborators: Novartis; Odense University Hospital
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• Patients diagnosed with breast cancer and metastases to bone.

• Patients diagnosed with multiple myeloma.

• Patients who are scheduled to receive Zometa.

• Post-menopausal women (at least 10 months since last period).

• Newly diagnosed patients must have clear signs of osteolysis.

Exclusion Criteria:

• Anti-estrogen treatment.

• Patients given chemotherapy during or less than 7 days before study begin.

• Patients receiving glucocorticoids less than 5 days prior to study begin or during the study period (14 days)